{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"25.0","value":"16.7"},{"groupId":"OG001","lowerLimit":"10.8","upperLimit":"32.3","value":"20.3"},{"groupId":"OG002","lowerLimit":"11.4","upperLimit":"24.6","value":"18.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"139"}],"units":"Participants"}],"description":"Skin response was primarily classified based on an assessment using mSWAT, provided there was documented evidence of stable disease or better in lymph node/viscera.The mSWAT is a tool specifically developed to evaluate the extent of skin disease in CTCL (Olsen et al 2007).\n\nResponses in the skin based on SWAT are defined as:\n\n* Complete Response (CR): no evidence of skin disease\n* Partial Response (PR): ≥ 50% decrease of the modified SWAT score compared with baseline\n* Stable Disease (SD): Neither CR, PR, or PD as compared with baseline, i.e. change from baseline is less than a 50% decrease but also less than a 25 % increase in the modified SWAT score\n* Progressive Disease (PD): ≥ 25% increase in the modified SWAT score compared with baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"Bexarotene Exposed"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG001","title":"Bexarotene Naive"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG002","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"The analysis was performed in Full Analysis Set (FAS) population was defined according to the intention-to-treat principle. This population will include all participants enrolled into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to 6 Months of Follow up","title":"Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT)","type":"PRIMARY","unitOfMeasure":"percentage"}